이엔셀

456070KOSDAQ기초 의약물질 제조업

46.1 / 100

Reference Date: 2026-04-13

Financial Score8.5 / 40

News Sentiment19.6 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Declined 10.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InCell operates two business models based on its GMP technology for cell and gene therapy drug development: CDMO (Contract Development and Manufacturing Organization) for advanced biopharmaceuticals and the development of next-generation cell and gene therapy drugs. The company holds the only GMP facility in South Korea capable of simultaneous cell and virus production, focusing on therapies for rare diseases like Charcot-Marie-Tooth and Duchenne muscular dystrophy.

Number of Employees

112people

Average Salary

42.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

3.99Industry Average 2.031.0Point

2.0x industry avg (risky)

ROE

-36.79Industry Average -4.293.5Point

8.6x industry avg (excellent)

Debt Ratio

53.53Industry Average 6.610.0Point

8.1x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼27.1% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.0% (declining, 2yr)

Detailed News Sentiment

7 totalPositive 5Neutral 0Negative 0Average Sentiment Score 90

Positive
이엔셀, 바이오 유럽서 20여개 글로벌社와 CMT 치료제 기술이전 논의
이엔셀이 바이오 유럽에서 20여개 글로벌 기업과 핵심 파이프라인 'EN001'의 기술이전을 논의했습니다.
Positive
이엔셀, ‘세포 안테나 재생’ 핵심 특허 日 등록…"항노화 시장 선점....
이엔셀이 세포의 핵심 신호전달 체계인 '일차 성모' 기능을 복구·강화하는 독자적 기전의 일본 특허 등록을 완료했습니다.
Positive
이엔셀, 근감소증 치료제 임상 1/2상 시험계획변경승인
이엔셀이 자체 개발 중인 근감소증 치료제 'EN001'에 대해 식품의약품안전처로부터 임상 1/2상 시험계획변경승인을 받았습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (41%)

Current 14,280Won52-week high 20,15052-week low 10,040

1-month return1.0Point

1m -10.41% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral주식등의대량보유상황보고서(일반)2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral투자판단관련주요경영사항(임상시험계획변경승인) (근감소증 환자를 대상으로 EN001의 유효성 및 안전성 평가를 위한 다기관, 무작위배정, 이중눈가림, 위약대조 임상시험 계획 변경승인)2026-03-20
Neutral감사보고서제출2026-03-20